Zhao Weili
赵维莅
Chief Physician, Professor, Doctoral Supervisor; Vice President of Ruijin Hospital
Lymphoid malignancies, especially lymphoma and leukemia, with translational hematologic oncology research including diffuse large B-cell lymphoma and CAR-T-related therapeutic strategy research(淋巴细胞恶性疾病，重点为淋巴瘤和白血病，以及弥漫大B细胞淋巴瘤等血液肿瘤转化研究与CAR-T相关治疗策略研究)
23+ career cases
(haodf.com)Leadership & Positions
- Vice President, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
- Executive Deputy Director, Shanghai Institute of Hematology
- Executive Deputy Director, Department of Hematology, Ruijin Hospital
- Deputy Director, Hematology Branch, Chinese Medical Association
- Secretary-General, Chinese Society of Experimental Hematology
- Vice Chair, CSCO Anti-Lymphoma Alliance
Languages
Notable Publications
Germ layer specification and organotropism in lymphoma invasion.
Science Bulletin (2026) — co-author
PubMed/DOIGenetic and Transcriptomic Profiles Identify Potential Therapeutic Targets of Concurrent Follicular and Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma.
Hematological Oncology (2026) — co-author
PubMed/DOIResponse-adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A retrospective observational study.
Clinical and Translational Medicine (2025) — co-author
PubMed/DOIPioneering Contributions
- Built a national-level clinical and translational research program in lymphoid malignancies at Ruijin Hospital and the Shanghai Institute of Hematology, focused on lymphoma and leukemia.
- Advanced molecular and transcriptomic characterization of aggressive B-cell lymphomas to identify therapeutic targets and biologic mechanisms of progression and invasion.
- Contributed to CAR-T-related therapeutic strategy research in relapsed/refractory large B-cell lymphoma, including response-adapted combination approaches to improve CD19 CAR-T outcomes.
Sources — Zhao Weili
- https://www.rjh.com.cn/2018RJPortal/rjksyzj/rjksyzjcxlb/index.shtml?xm=%E8%B5%B5...—Official Ruijin expert directory verification of identity, department, title, clinic schedule, and image path(accessed Apr 16, 2026)
- https://www.rjh.com.cn/intertidwebapp/custom/CustomJson—Official Ruijin structured expert data for biography, hospital leadership roles, academic appointments, subspecialty focus, and headshot path(accessed Apr 16, 2026)
- https://www.rjh.com.cn/2018RJPortal/rjksyzj/zjxq/index.shtml?ks=%E8%A1%80%E6%B6%...—Official Ruijin hospital profile URL confirmation(accessed Apr 16, 2026)
- https://www.haodf.com/doctor/259467/xinxi-jieshao.html—Secondary biography confirmation, title, research scope, and Ruijin/Shanghai Institute of Hematology affiliations(accessed Apr 16, 2026)
- https://www.haodf.com/doctor/259467/pingjia-zhenliao.html?siftkey=all—Cumulative case-volume proxy via 23 post-visit evaluations and disease breakdown including lymphoma and leukemia(accessed Apr 16, 2026)
- https://pubmed.ncbi.nlm.nih.gov/41721413/—Publication and Ruijin affiliation verification(accessed Apr 16, 2026)
- https://pubmed.ncbi.nlm.nih.gov/41852166/—Publication verification in lymphoma genomics(accessed Apr 16, 2026)
- https://pubmed.ncbi.nlm.nih.gov/41904054/—Publication verification in lymphoma invasion biology(accessed Apr 16, 2026)
- https://pubmed.ncbi.nlm.nih.gov/40268516/—Publication verification for CAR-T-related therapeutic strategy research in relapsed/refractory large B-cell lymphoma(accessed Apr 16, 2026)
Request a case review with Zhao Weili
Zhao Weili practices at The Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine in Shanghai.
Request Case Review